Genetic modification of T cells

Cancer Journal (United States)

Volumn 20, Issue 2, 2014, Pages 145-150

  Morgan, Richard A ^a   Kakarla, Sunitha ^a  

^a BLUEBIRD BIO   (United States)

Author keywords

chimeric antigen receptor; electroporation; Gene therapy; lentivirus; retrovirus; transposon

Indexed keywords

GAMMA RETROVIRAL VECTOR; LENTIVIRUS VECTOR; MESSENGER RNA; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; TRANSPOSON;

B LYMPHOCYTE; DNA MODIFICATION; ELECTROPORATION; GENE TRANSFER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRANSPOSON; VIRAL GENE THERAPY; GENE VECTOR; GENETICS; LENTIVIRINAE; PROCEDURES; RETROVIRUS;

DNA TRANSPOSABLE ELEMENTS; ELECTROPORATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LENTIVIRUS; RETROVIRIDAE; RNA, MESSENGER;

EID: 84897494749     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000033     Document Type: Review

References (49)

1. Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med. 2001;7:33-40.
2. Baum C, Schambach A, Bohne J, et al. Retrovirus vectors: toward the plentivirus? Mol Ther. 2006;13:1050-1063.
3. Lynch CM, Miller AD. Production of high-titer helper virus-free retroviral vectors by cocultivation of packaging cells with different host ranges. JVirol. 1991;65:3887-3890.
4. Suerth JD, Schambach A, Baum C. Genetic modification of lymphocytes by retrovirus-based vectors. Curr Opin Immunol. 2012;24:598-608.
5. Engels B, Cam H, Schuler T, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther. 2003;14:1155-1168.
6. Brentjens RJ, Latouche J-B, Santos E, et al. Eradication of systemic Bcell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286.
7. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709-2720.
8. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264-1270.
9. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38-.
10. Zufferey R, Donello JE, Trono D, et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. 1999;73:2886-2892.
11. Lamers CH, Willemsen R, van EP, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood. 2011;117:72-82.
12. Kochenderfer JN, Dudley ME, Carpenter RO, et al. Donor-derived CD19- targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129-4139.
13. Cruz CR, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122:2965-2973.
14. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118:3143-3150.
15. Lewinski MK, Bushman FD. Retroviral DNA integration - mechanism and consequences. Adv Genet. 2005;55:147-181.
16. Newrzela S, Cornils K, Li Z, et al. Resistance of mature T cells to oncogene transformation. Blood. 2008;112:2278-2286.
17. Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012;4:132ra53-.
18. Ellis J. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther. 2005;16:1241-1246.
19. Loew R, Meyer Y, Kuehlcke K, et al. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gammaretroviral vectors using targeted integration. Gene Ther. 2010;17:272-280.
20. Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol Ther. 2010;18:477-490.
21. Zennou V, Petit C, Guetard D, et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell. 2000;101:173-185.
22. Cronin J, Zhang XY, Reiser J. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 2005;5:387-398.
23. Ciuffi A. Mechanisms governing lentivirus integration site selection. Curr Gene Ther. 2008;8:419-429.
24. Pistello M, Vannucci L, Ravani A, et al. Streamlined design of a selfinactivating feline immunodeficiency virus vector for transducing ex vivo dendritic cells and T lymphocytes. Genet Vaccines Ther. 2007;5:8-.
25. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72:8463-8471.
26. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267.
27. Korin YD, Zack JA. Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol. 1998;72:3161-3168.
28. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009; 17:1453-1464.
29. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509-1518.
30. Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73-.
31. Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther. 2004;4:683-696.
32. Ziegler L, Yang L, Joo K, et al. Targeting lentiviral vectors to antigenspecific immunoglobulins. Hum Gene Ther. 2008;19:861-872.
33. Maurice M, Verhoeyen E, Salmon P, et al. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood. 2002;99:2342-2350.
34. Frecha C, Costa C, Negre D, et al. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudo typed with measles virus glycoproteins. Blood. 2008;112:4843-4852.
35. Yanez-Munoz RJ, Balaggan KS, MacNeil A, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med. 2006;12:348-353.
36. Bank A, Dorazio R, Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci. 2005;1054:308-316.
37. Cartier N, Aubourg P. Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy. Curr Opin Mol Ther. 2008;10:471-478.
38. Izsvak Z, Hackett PB, Cooper LJ, et al. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. BioEssays. 2010;32:756-767.
39. Ivics Z, Izsvak Z. Nonviral gene delivery with the sleeping beauty transposon system. Hum Gene Ther. 2011;22:1043-1051.
40. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68:2961-2971.
41. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010;18:674-683.
42. Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/ transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21:427-437.
43. Nakazawa Y, Huye LE, Salsman VS, et al. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2- specific chimeric antigen receptor. Mol Ther. 2011;19:2133-2143.
44. Wilson MH, Coates CJ, George AL Jr. PiggyBac transposon-mediated gene transfer in human cells. Mol Ther. 2007;15:139-145.
45. Tavernier G, Andries O, Demeester J, et al. mRNA as gene therapeutic: how to control protein expression. J Control Release. 2011;150:238-247.
46. Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843-851.
47. Zhao Y, Moon E, Carpenito C, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 2010;70:9053-9061.
48. Yoon SH, Lee JM, Cho HI, et al. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/ neu-specific chimeric immune receptor in ovarian cancer xenograft model. Cancer Gene Ther. 2009;16:489-497.
49. Barrett DM, Zhao Y, Liu X, et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther. 2011;22:1575-1586